Physician profile
Larry Levinson
NPI 1174572531
$12,897.96
in general payments reported to CMS, 2019-2025
35 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $1,000 · 2021: $2,744 · 2022: $1,912 · 2023: $2,060 · 2024: $1,440 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,385.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,233.17 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,539.88 | 2020-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,489.52 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Lilly USA, LLC | $737.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $721.68 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $712.90 | 2019-2022 | |
| Amgen INC. | $587.22 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $513.44 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $483.85 | 2019-2025 | Capvaxive, Steglatro |
| Glaxosmithkline, LLC. | $464.22 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Heartflow, INC. | $418.55 | 2023-2025 | Ffrct |
| Bayer Healthcare Pharmaceuticals INC. | $291.83 | 2021 | |
| Esperion Therapeutics, INC. | $167.10 | 2021-2024 | Nexletol |
| Angiodynamics, INC. | $159.61 | 2023 | Nanoknife |
| Pfizer INC. | $155.45 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $148.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Ardelyx, INC. | $124.99 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $118.07 | 2019-2023 | |
| Viiv Healthcare Company | $89.63 | 2025 | Apretude |
| Verity Pharmaceuticals INC. | $83.10 | 2024-2025 | Tlando |
| Terumo Medical Corporation | $62.50 | 2025 | R2p Misago, Azur Cx Detachable |
| Abbott Laboratories | $61.94 | 2022-2025 | Freestyle Libre |
| Tolmar, INC. | $48.12 | 2023-2024 | |
| Amarin Pharma, INC. | $44.56 | 2019-2021 | |
| Halozyme INC | $35.63 | 2023 | |
| Gilead Sciences, INC. | $27.46 | 2025 | |
| Optinose US, INC. | $23.23 | 2025 | |
| Ethicon US, LLC | $21.85 | 2019 | |
| Neurocrine Biosciences, INC. | $18.30 | 2023 | Ingrezza |
| Kowa Pharmaceuticals America, INC. | $16.77 | 2021 | |
| Antares Pharma, INC. | $16.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.05 | 2022 | |
| Aytu Biopharma, INC. | $14.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.